SPONSOR
Jiangsu HengRui Medicine Co., Ltd.
Total Trials
9
Recruiting
9
Phases
Phase 1, Phase 3, Phase 1, Phase 2, Phase 2, Phase 4
Conditions studied: Advanced Solid TumorAdvanced Gastroenteropancreatic Neuroendocrine TumorProstate CancerRecurrent or Metastatic Cervical CancerLocal Analgesia Via InfiltrationAdvanced Non-small Cell Lung CancerPatients With Solid TumorsMalignant Solid Tumor
Jiangsu HengRui Medicine Co., Ltd. is a clinical research sponsor with 9 registered studies on ClinicalTrials.gov, of which 9 are actively recruiting participants. Research covers conditions including Advanced Solid Tumor, Advanced Gastroenteropancreatic Neuroendocrine Tumor, Prostate Cancer, Recurrent or Metastatic Cervical Cancer.
The trial portfolio spans Phase 1, Phase 3, Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Jiangsu HengRui Medicine Co., Ltd.
How many clinical trials has Jiangsu HengRui Medicine Co., Ltd. sponsored?
ClinicalMetric currently tracks 9 clinical trials sponsored by Jiangsu HengRui Medicine Co., Ltd., of which 9 are actively recruiting participants. These trials cover conditions including Advanced Solid Tumor, Advanced Gastroenteropancreatic Neuroendocrine Tumor, Prostate Cancer. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Jiangsu HengRui Medicine Co., Ltd. research focus on?
Jiangsu HengRui Medicine Co., Ltd. clinical trials span Advanced Solid Tumor, Advanced Gastroenteropancreatic Neuroendocrine Tumor, Prostate Cancer, Recurrent or Metastatic Cervical Cancer, Local Analgesia Via Infiltration, and additional conditions. The research pipeline includes Phase 1, Phase 3, Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Jiangsu HengRui Medicine Co., Ltd. clinical trial?
To participate in a Jiangsu HengRui Medicine Co., Ltd. trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Jiangsu HengRui Medicine Co., Ltd. trials with current recruitment status updated daily.
Clinical Trials by Jiangsu HengRui Medicine Co., Ltd.
NCT07380334 Phase 1
Recruiting
A Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-1049 in Patients With Advanced Solid Tumors
Advanced Solid Tumor
NCT05884255 Phase 3
Recruiting
An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.
Advanced Gastroenteropancreatic Neuroendocrine Tumor
NCT07407283 Phase 1, Phase 2
Recruiting
A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer
Prostate Cancer
NCT07051486 Phase 2
Recruiting
A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer
Recurrent or Metastatic Cervical Cancer
NCT06344091 Phase 4
Recruiting
A Study of Bupivacaine Liposome Injection in Local Analgesia of Pediatric Patients
Local Analgesia Via Infiltration
NCT05482568 Phase 1, Phase 2
Recruiting
A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer
Advanced Non-small Cell Lung Cancer
NCT07711184 Phase 1
Recruiting
A Clinical Study of HRS-7525 Tablets in Patients With Advanced Prostate Cancer
Prostate Cancer
NCT07070349 Phase 1, Phase 2
Recruiting
A Trial of HRS-6213 in Healthy Subjects and Patients With Solid Tumors
Patients With Solid Tumors
NCT06735144 Phase 1, Phase 2
Recruiting
Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors
Malignant Solid Tumor
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology